{"doi":"10.1093/jac/dkab319","title":"Pharmacokinetics of bictegravir, emtricitabine and tenofovir alafenamide in a gastrectomized patient with HIV","abstract":"Mann-Whitney test). However, based on the association between baseline IC 50 values .100 nM and poor virological response during 8 day fostemsavir monotherapy, 9 there was only one virus that could be less susceptible to the activity of fostemsavir in vivo (sample CI-147290). Interestingly, this virus harboured the unusual amino acid variant proline at the key fostemsavir resistance codon 426 of the gp120 coding region. Indeed, the most prevalent amino acid variants occurring at codon 426 in env sequences retrieved from the Los Alamos National Laboratory Database are M (93.6%), L (4.8%) and I/ K/R (0.5% each) in CRF02_AG and M (67.9%), R (21.6%), L (8.2%) and K (1.3%) in subtype B. To investigate the role of the different variants, we constructed the M426P, L, K and R site-directed mutants in the NL4-3 subtype B backbone and tested their susceptibility to temsavir (Table Indeed, the M426P mutant was 4-fold less susceptible than the wild-type M426, although it was not as resistant as the canonical M426L mutant, suggesting that the rarely occurring P variant could contribute to the observed phenotype in sample CI-147290, together with other undetermined changes. Limited availability of the RNA extract did not allow further analysis of the role of the M426P mutation and other polymorphisms in this isolate.","journal":"Journal of Antimicrobial Chemotherapy","year":2021,"id":206874,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9349,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":531454,"name":"Antonio D’Avolio","orcid":"0000-0002-1321-4126","position":1,"is_corresponding":false},{"id":791833,"name":"Amedeo De Nicolò","orcid":"0000-0002-5973-9948","position":2,"is_corresponding":false},{"id":228459,"name":"Chiara Agrati","orcid":"0000-0002-5252-0927","position":3,"is_corresponding":false},{"id":240149,"name":"Andrea Antinori","orcid":"0000-0003-2121-4684","position":4,"is_corresponding":false},{"id":791834,"name":"Stefania Cicalini","orcid":"0000-0002-0754-6917","position":5,"is_corresponding":false},{"id":272462,"name":"Massimo Tempestilli","orcid":"0000-0003-3107-7441","position":0,"is_corresponding":true}],"reference_count":6,"raw_metadata":null,"created_at":"2026-07-18T23:51:45.688025Z","pmid":"34450632","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}